Answers are grounded in this paper and cite their sources.
Recommendations evolve to emphasize molecular monitoring and personalized management in chronic myeloid leukemia, highlighting precision medicine benefits.
Over time, ELN recommendations have shifted from cytogenetic to molecular monitoring, incorporated second-generation TKIs, and introduced treatment-free remission as a major therapeutic goal. The latest framework emphasizes personalized CML management by integrating molecular response with patient-specific factors, reflecting the broader evolution of precision medicine in hematology.
No takes yet. Share an insight, caveat, or question.
Yolcu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: